Results 131 to 140 of about 11,256 (207)

Sensitizing Colorectal Cancer to PARP Inhibitors: Biomarkers, Mechanisms, and Combination Strategies. [PDF]

Int J Mol Sci
Elesnawy M, Masood E, Naik A.
europepmc   +1 more source

The cGAS-STING pathway in ovarian cancer: from genomic instability to immunotherapeutic vulnerability. [PDF]

Front Immunol
Chen HH, Ni FX, Huang DH, Jiang ZB.
europepmc   +1 more source

Chromatin adaptation and histone remodeling as mechanisms of PARP inhibitor resistance and therapeutic vulnerability. [PDF]

Front Pharmacol
Bae W, Ra EA, Lee MH.
europepmc   +1 more source

Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian carcinoma after poly-ADP-ribose polymerase inhibitors progression: A real-world single-center experience. [PDF]

Gynecol Oncol Rep
Amondarain Amenabar N, Mujika Eizmendi K, Gabirondo Amenabar L, Crespo Cruz M, Muñagorri Quiles I, Gutiérrez San José E, García Álvarez M, Arrondo Arizmendi I, Bengoa Fernández N, Martínez Amorena J, Sánchez Urrestarazu M, Egaña Otaño L, Churruca Galaz C.   +12 more
europepmc   +1 more source

Integrative proteomics reveals MSH6 to modulate PARP inhibitor sensitivity in BRCA1/2-proficient ovarian cancer. [PDF]

PLoS One
Deng O, Nepomuceno TDC, Fang B, Welsh EA, Izumi V, Martin RH, George EM, Koomen JM, Monteiro AN, Rix U.   +9 more
europepmc   +1 more source

Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation. [PDF]

Signal Transduct Target Ther
Camps-Fajol C, Minguillón J, Surrallés J.   +2 more
europepmc   +1 more source

The dual immune landscape of homologous recombination-deficient tumors: mechanisms and therapeutic implications. [PDF]

Cancer Metastasis Rev
Yang Y, Yin Y, Rong S, Qian Y, Li D, Zhang Y, Wang X.   +6 more
europepmc   +1 more source

STN1 upregulation promotes PARPi resistance in BRCA2-deficient cancer cells via replication fork protection and suppression of ssDNA gap formation. [PDF]

NAR Cancer
Laghari ZA, Li N, Gayybov S, Wang QE, Chai W.   +4 more
europepmc   +1 more source

Treatment Sequencing in ARPI-Pre-Exposed Metastatic Castration-Resistant Prostate Cancer: Radioligand Therapy, PARP Inhibitors, and Antibody-Drug Conjugates. [PDF]

Cancers (Basel)
Sharaf B, Al-Rwashdeh M, El Khatib O, Al-Ibraheem A, Abu Fara A, Ismail A, Alkasrawi H, Abdalla M, Jehad S.   +8 more
europepmc   +1 more source

Targeting the DNA Damage Response in Cancer. [PDF]

MedComm (2020)
Qiao Y, Kang B, Zhang J, Zhang R, Li J.
europepmc   +1 more source